Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 06, 2021 08:00 ET | Source: Sumitovant Biopharma

Altavant Sciences Advances Rodatristat Ethyl into Phase 2b Clinical Trial for Pulmonary Arterial Hypertension

Cary, N.C. and Basel, Switzerland, May 06, 2021 (GLOBE NEWSWIRE) -- Altavant Sciences, a clinical-stage biopharmaceutical company focused on patient-centric drug development in rare respiratory...
April 26, 2021 11:34 ET | Source: Sumitovant Biopharma

Cary, N.C. and Basel, Switzerland s Finds Nebulized ALTA-2530 Retains Potency and Reaches Target Lung Tissues, Supporting Continued Investigation for Treatment of BOS

Cary, N.C. and Basel, Switzerland, April 26, 2021 (GLOBE NEWSWIRE) -- – Altavant Sciences, a clinical-stage biopharmaceutical company focused on patient-centric drug development in rare respiratory...
April 21, 2021 08:00 ET | Source: Sumitovant Biopharma

Altavant Sciences Highlights Pipeline Progress in PAH and BOS at the International Society for Heart & Lung Transplantation Meeting

Cary, N.C. and Basel, Switzerland, April 21, 2021 (GLOBE NEWSWIRE) -- – Altavant Sciences, a clinical-stage biopharmaceutical company focused on patient-centric drug development in rare respiratory...
March 29, 2021 08:00 ET | Source: Sumitovant Biopharma

Sumitovant Biopharma Completes Acquisition of Urovant Sciences

NEW YORK, LONDON, IRVINE, CA & BASEL, SWITZERLAND, March 29, 2021 (GLOBE NEWSWIRE) -- Sumitovant Biopharma and Urovant Sciences (formerly Nasdaq: UROV) jointly announced today the completion of...
March 02, 2021 07:00 ET | Source: Sumitovant Biopharma

Sumitovant Biopharma’s Portfolio of Innovative Companies Achieve Significant Clinical and Corporate Milestones in its Third Quarter of Operation

LONDON and NEW YORK, March 02, 2021 (GLOBE NEWSWIRE) -- — Sumitovant Biopharma. today announced that its five subsidiary healthcare companies (Myovant, Urovant, Enzyvant, Altavant and Spirovant )...
February 18, 2021 07:00 ET | Source: Sumitovant Biopharma

Altavant Sciences Initiates Chemical Lung Injury Program in Collaboration with the BARDA and NIAID

Cary, N.C. and Basel, Switzerland, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Altavant Sciences, a clinical-stage biopharmaceutical company focused on patient-centric drug development in rare respiratory...
February 17, 2021 20:02 ET | Source: Sumitovant Biopharma

Sumitovant Biopharma Announces Publication in the New England Journal of Medicine of Myovant Sciences Phase 3 LIBERTY Studies of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids

New York, London, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Sumitovant Biopharma Ltd., a majority shareholder of Myovant Sciences (NYSE: MYOV), announced today that the New England Journal of Medicine...
January 26, 2021 17:27 ET | Source: Sumitovant Biopharma

UPDATE: Sumitovant Biopharma Announces Myovant Sciences Positive One-Year Data from Phase 3 SPIRIT Extension Study of Once-Daily Relugolix Combination Therapy in Women with Endometriosis

NEW YORK, LONDON,, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Sumitovant Biopharma Ltd., a majority shareholder of Myovant Sciences (NYSE: MYOV), announced today that Myovant Sciences’ Phase 3 SPIRIT...
January 26, 2021 14:28 ET | Source: Sumitovant Biopharma

Sumitovant Biopharma Announces Myovant Sciences Positive One-Year Data from Phase 3 SPIRIT Extension Study of Once-Daily Relugolix Combination Therapy in Women with Endometriosis

NEW YORK, LONDON,, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Sumitovant Biopharma Ltd., a majority shareholder of Myovant Sciences (NYSE: MYOV), announced today that Myovant Sciences’ Phase 3 SPIRIT...
January 26, 2021 07:00 ET | Source: Sumitovant Biopharma

Spirovant Continues Rapid Growth with New Headquarters and Expanded Leadership

PHILADELPHIA, PA, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Spirovant Sciences, a gene therapy company developing treatments and cures for respiratory diseases including cystic fibrosis, today announced the...

Next Page keyboard_arrow_right